Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for genotropin

  1. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

    Technology appraisal guidance
    Published
    26 May 2010
    View recommendations

    Sections for TA188

  2. Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)

    Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over.

    Technology appraisal guidance
    Published
    1 February 2023
    View recommendations

    Sections for TA863

  3. Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.

    Technology appraisal guidance
    Published
    27 August 2003
    View recommendations

    Sections for TA64

  4. Human Growth Hormone for Idiopathic Short Stature (in children)[ID317]

    Discontinued [GID-TA11256]

    Technology appraisal guidance
    Discontinued